These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 26675716)
1. Using surface plasmon resonance spectroscopy to characterize the inhibition of NGF-p75(NTR) and proNGF-p75(NTR) interactions by small molecule inhibitors. Sheffield KS; Vohra R; Scott JA; Ross GM Pharmacol Res; 2016 Jan; 103():292-9. PubMed ID: 26675716 [TBL] [Abstract][Full Text] [Related]
2. Characterizing nerve growth factor-p75(NTR) interactions and small molecule inhibition using surface plasmon resonance spectroscopy. Sheffield KS; Kennedy AE; Scott JA; Ross GM Anal Biochem; 2016 Jan; 493():21-6. PubMed ID: 26435172 [TBL] [Abstract][Full Text] [Related]
3. Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-(benzolylamino)-4,9-dihydro-4-methyl-9-oxo-pyrazolo[5,1-b]quinazoline-2-carboxylic acid] suggests altered NGF-p75NTR interactions in the presence of TrkA. Colquhoun A; Lawrance GM; Shamovsky IL; Riopelle RJ; Ross GM J Pharmacol Exp Ther; 2004 Aug; 310(2):505-11. PubMed ID: 15051797 [TBL] [Abstract][Full Text] [Related]
4. NGF ligand alters NGF signaling via p75(NTR) and trkA. Niederhauser O; Mangold M; Schubenel R; Kusznir EA; Schmidt D; Hertel C J Neurosci Res; 2000 Aug; 61(3):263-72. PubMed ID: 10900073 [TBL] [Abstract][Full Text] [Related]
5. Epicatechin blocks pro-nerve growth factor (proNGF)-mediated retinal neurodegeneration via inhibition of p75 neurotrophin receptor expression in a rat model of diabetes [corrected]. Al-Gayyar MM; Matragoon S; Pillai BA; Ali TK; Abdelsaid MA; El-Remessy AB Diabetologia; 2011 Mar; 54(3):669-80. PubMed ID: 21136036 [TBL] [Abstract][Full Text] [Related]
6. Fabry disease-associated globotriaosylceramide induces mechanical allodynia via activation of signaling through proNGF-p75 Sugimoto J; Satoyoshi H; Takahata K; Muraoka S Eur J Pharmacol; 2021 Mar; 895():173882. PubMed ID: 33482180 [TBL] [Abstract][Full Text] [Related]
7. Antagonism of proNGF or its receptor p75 Mossa AH; Galan A; Cammisotto PG; Velasquez Flores M; Shamout S; Barcelona P; Saragovi HU; Campeau L Diabetologia; 2020 Sep; 63(9):1932-1946. PubMed ID: 32699962 [TBL] [Abstract][Full Text] [Related]
8. A Pro-Nerve Growth Factor (proNGF) and NGF Binding Protein, α2-Macroglobulin, Differentially Regulates p75 and TrkA Receptors and Is Relevant to Neurodegeneration Ex Vivo and In Vivo. Barcelona PF; Saragovi HU Mol Cell Biol; 2015 Oct; 35(19):3396-408. PubMed ID: 26217017 [TBL] [Abstract][Full Text] [Related]
9. Identification of novel pyrazoloquinazolinecarboxilate analogues to inhibit nerve growth factor in vitro. Eibl JK; Strasser BC; Ross GM Eur J Pharmacol; 2013 May; 708(1-3):30-7. PubMed ID: 23528360 [TBL] [Abstract][Full Text] [Related]
10. Up-regulation of pro-nerve growth factor, neurotrophin receptor p75, and sortilin is associated with retrovirus-induced spongiform encephalomyelopathy. Stoica G; Lungu G; Kim HT; Wong PK Brain Res; 2008 May; 1208():204-16. PubMed ID: 18395188 [TBL] [Abstract][Full Text] [Related]
11. Nerve growth factor (NGF)-mediated regulation of p75(NTR) expression contributes to chemotherapeutic resistance in triple negative breast cancer cells. Chakravarthy R; Mnich K; Gorman AM Biochem Biophys Res Commun; 2016 Sep; 478(4):1541-7. PubMed ID: 27577679 [TBL] [Abstract][Full Text] [Related]
12. Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway. Elshaer SL; Alwhaibi A; Mohamed R; Lemtalsi T; Coucha M; Longo FM; El-Remessy AB Diabetologia; 2019 Aug; 62(8):1488-1500. PubMed ID: 31073629 [TBL] [Abstract][Full Text] [Related]